Dalzanemdor clinical trials
Also written SAGE-718.
How each study uses dalzanemdor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SAGE-718
- 11
Studies by the year they started
11 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses dalzanemdor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's DiseaseTerminatedPhase 3Supernus Pharmaceuticals, Inc.NCT05655520Written as SAGE-718
- A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03770780Written as SAGE-718
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03787758Written as SAGE-718
- A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03771586Written as SAGE-718
- A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy SubjectsCompletedPhase 1Supernus Pharmaceuticals, Inc.NCT03844906Written as SAGE-718
- A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05619692Written as SAGE-718
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT04476017Written as SAGE-718
- A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT04602624Written as SAGE-718
- A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)CompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05107128Written as SAGE-718
- 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's DiseaseCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05358821Written as SAGE-718
- A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05318937Written as SAGE-718
Codes
What other systems call dalzanemdor · ClinicalTrials.gg INT015651
- UNII (FDA) 8ENS5K3JW8DALZANEMDOROne source FDA
- NCI Thesaurus C190332DalzanemdorOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8ENS5K3JW8 | DALZANEMDOR | One source FDA |
| NCI Thesaurus | C190332 | Dalzanemdor | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.